Novo GLP-1 drug shows less lean mass loss than rivals, study says

As weight‑loss drugs surge in popularity, a study raises a new question about what patients may be losing along the way.
BioSpace

Novo may have muscle advantage over Lilly in weight-loss race: preprint

More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, ...
Morning Overview on MSN

GLP-1 pioneers test obesity drugs that work even without GLP-1 signaling

For the past three years, nearly every breakthrough in obesity medicine has traced back to a single class of drugs: GLP-1 ...

Novo obesity drug outperforms Lilly’s in preserving lean body mass: study

Eli Lilly’s (LLY) obesity therapy tirzepatide can lead to greater weight loss but with a higher impact on lean body mass ...
STAT

Veru says its drug preserved lean mass in patients taking Wegovy

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Veru said Monday that its ...
KGOU

Quit a GLP-1? Plan to start again? It's not recommended, but plenty of people do it

A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again.

Study looks into which weight-loss drug makes you lose the most muscle

A new study suggests that Eli Lilly’s GLP-1 drug tirzepatide, marketed as Zepbound and Mounjaro, leads to greater overall ...
Reuters

Scholar Rock's drug helps Zepbound patients retain more muscle in trial

The reduction of muscle accompanying weight-loss drugs such as Lilly's Zepbound and Novo's Wegovy has left some doctors concerned about a possible decrease in overall strength, especially in older ...